verapamil has been researched along with Anti-MuSK Myasthenia Gravis in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenous verapamil (18 micrograms, 36 micrograms, 72 micrograms kg-1) on neuromuscular transmission were studied in the integrated electromyographic (IEMG) responses of indirectly stimulated thenar muscles of five myasthenia gravis patients and 12 other patients without neuromuscular diseases anesthetized with thiopentone, pethidine and nitrous oxide in oxygen." | 7.67 | Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis. ( Ho, ST; Lee, SC, 1987) |
| "The effects of intravenous verapamil (18 micrograms, 36 micrograms, 72 micrograms kg-1) on neuromuscular transmission were studied in the integrated electromyographic (IEMG) responses of indirectly stimulated thenar muscles of five myasthenia gravis patients and 12 other patients without neuromuscular diseases anesthetized with thiopentone, pethidine and nitrous oxide in oxygen." | 3.67 | Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis. ( Ho, ST; Lee, SC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wirguin, I | 1 |
| Brenner, T | 1 |
| Sicsic, C | 1 |
| Argov, Z | 1 |
| Reverte, M | 1 |
| Matell, G | 1 |
| Bjelak, S | 1 |
| Jonkers, I | 1 |
| Pirskanen, R | 1 |
| Van Vliet, J | 1 |
| Swerup, C | 1 |
| Swash, M | 1 |
| Ingram, DA | 1 |
| Casado, I | 1 |
| Nevado, L | 1 |
| Dorrego, FG | 1 |
| Lee, SC | 1 |
| Ho, ST | 1 |
6 other studies available for verapamil and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Variable effect of calcium channel blockers on the decremental response in experimental autoimmune myasthenia gravis.
Topics: Action Potentials; Animals; Electric Stimulation; Muscles; Myasthenia Gravis; Nimodipine; Rabbits; T | 1994 |
Adverse effect of verapamil in myasthenia gravis: an additional comment.
Topics: Humans; Hypokalemia; Myasthenia Gravis; Verapamil | 1993 |
Calcium channel and beta-receptor antagonists and agonists in MG.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Calcium Channel Blocker | 1998 |
Adverse effect of verapamil in myasthenia gravis.
Topics: Contraindications; Coronary Artery Bypass; Coronary Disease; Electromyography; Humans; Male; Middle | 1992 |
[Myasthenia associated with verapamil].
Topics: Aged; Female; Humans; Myasthenia Gravis; Verapamil | 1989 |
Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis.
Topics: Adult; Blood Pressure; Electrocardiography; Electromyography; Female; Heart Rate; Humans; Male; Midd | 1987 |